Seres Therapeutics, Inc.

Stage 4 · Declining · week 34

As of Oct 22, 2026, Seres Therapeutics is in Stage 4, the downtrend phase, now in week 34 (since Feb 20, 2026). It closed at $2.13, 92.6% below its 52-week high and below its 200-day average, which is falling.

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. More about the company

$2.13

-7.39% today

$21.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MCRB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 25w

S1 13w

S4 20w

S4 35w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 25w → S1 2w → S4 1w → S1 1w → S4 12w → S1 13w → S2 4w → S3 1w → S4 13w → S1 8w → S4 20w → S1 6w → S2 11w → S3 4w → S2 1w → S3 9w → S4 35w current

Total tracked: 166 weeks across 17 stage runs.

MCRB among Biotechnology500th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…500	MCRBSeres Therapeutics, Inc.	Stage 4 · wk 34	8	−43.8%

vs 52W High

-92.6%

$2.13 lo$28.63 hi

92.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 34

1w13w26w

Week 34, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-71.7%

200 DMA: $7.52 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.06x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-43.8%

-57.1%

-73.7%

YTD

-85.9%

-88.6%

Scan Membership

Breakout Watch

Latest: 2024-09-05

4 appearances in last 60 days. First seen: 2020-05-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 34 · Vol 2.06x

2026-10-21S4

Wk 34 · Vol 0.63x

2026-10-20S4

Wk 34 · Vol 1.02x

2026-10-19S4

Wk 34 · Vol 0.35x

2026-10-16S4

Wk 34 · Vol 0.58x

2026-10-15S4

Wk 33 · Vol 0.36x

2026-10-14S4

Wk 33 · Vol 0.61x

2026-10-13S4

Wk 33 · Vol 0.64x

2026-10-12S4

Wk 33 · Vol 0.79x

2026-10-09S4

Wk 33 · Vol 1.16x

2026-10-08S4

Wk 32 · Vol 3.28x

2026-10-07S4

Wk 32 · Vol 0.93x

Moving averages & range

50 DMA

$3.93

200 DMA

$7.52

52W High

$28.63

52W Low

$2.13

5D Low

$2.13

Resistance levels (recent highs)

20d High

$3.52

60d High

$5.72

120d High

$8.14

250d High

$28.63

Next resistance

+65.3%

to 20d High

ROE

-66.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Seres Therapeutics: quick answers

What stage is Seres Therapeutics in?

As of Oct 22, 2026, Seres Therapeutics (MCRB) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 20, 2026 and is in week 34. What the four stages mean

Is Seres Therapeutics in an uptrend?

No. Seres Therapeutics is in a Stage 4 downtrend. It trades 71.7% below its 200-day average, which is falling.

How far is Seres Therapeutics from its 52-week high?

Seres Therapeutics closed at $2.13 on Oct 22, 2026, 92.6% below its 52-week high of $28.63. Its 52-week low is $2.13.

How has Seres Therapeutics performed over the past year?

As of Oct 22, 2026, Seres Therapeutics is down 88.6% over the past year and down 85.9% so far in 2026.

Which sector and industry is Seres Therapeutics in?

Seres Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.